menu
    • menu
    [{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Bharat Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"Covid 19 vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Washington University School of Medicine \/ Bharat Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Washington University School of Medicine \/ Bharat Biotech"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Precigen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"PRGN-3005","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Washington University School of Medicine \/ Washington University School of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"HT-ALZ","moa":"Amyloid beta protein","graph1":"Neurology","graph2":"Preclinical","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Washington University School of Medicine \/ Hoth Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Washington University School of Medicine \/ Hoth Therapeutics"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cilgavimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Washington University School of Medicine \/ Washington University School","highestDevelopmentStatusID":"12","companyTruncated":"Washington University School of Medicine \/ Washington University School"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Imago BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bomedemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Washington University School of Medicine \/ University of Washington School of Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Washington University School of Medicine \/ University of Washington School of Medicine"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Ocugen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"BBV154","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Washington University School of Medicine \/ Washington University","highestDevelopmentStatusID":"12","companyTruncated":"Washington University School of Medicine \/ Washington University"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"BostonGene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Washington University School of Medicine \/ Washington University School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Washington University School of Medicine \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Washington University School of Medicine \/ Washington University School of Medicine","highestDevelopmentStatusID":"2","companyTruncated":"Washington University School of Medicine \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"BioLineRx","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"Motixafortide","moa":"","graph1":"Hematology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Washington University School of Medicine \/ Washington University School of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Aprepitant","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Washington University School of Medicine \/ Washington University School of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ Washington University School of Medicine"}]

    Find Clinical Drug Pipeline Developments & Deals by Washington University School of Medicine

    Menu

    Washington University School of Medicine

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Washington University School of Medicine

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Washington University School of Medicine

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aprepitant

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Recipient : Hoth Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Hoth Therapeutics Announces Collaboration with First Active Clinical Site for its Phase 2 Trial to Treat Cance...

                            Details : The collaboration aims at activation of Washington University School of Medicine as the first clinical site in the CLEER-001 Phase 2a clinical trial of HT-001 (aprepitant) for the treatment for rash and skin disorders associated with EGFR inhibitor thera...

                            Brand Name : HT-001

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 08, 2023

                            Lead Product(s) : Aprepitant

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Recipient : Hoth Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Washington University School of Medicine

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Washington University School of Medicine

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Motixafortide,Natalizumab

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Recipient : BioLineRx

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            BioLineRx Announces Clinical Trial Collaboration with Washington University School of Medicine to Evaluate Mot...

                            Details : The aim of the collaboration is to advance a Phase 1 clinical trial that will evaluate the safety and feasibility of BL-8040 (motixafortide) to mobilize CD34+ hematopoietic stem cells (HSCs) for gene therapies in sickle cell disease (SCD).

                            Brand Name : BL-8040

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            March 06, 2023

                            Lead Product(s) : Motixafortide,Natalizumab

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Recipient : BioLineRx

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Washington University School of Medicine

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Washington University School of Medicine

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Discovery

                            Recipient : Eisai

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Eisai And Washington University School Of Medicine In St. Louis Enter Into Comprehensive Research Collaboratio...

                            Details : The collaboration strategically combines Washington University scientists’ expertise in the fundamental and clinical research in neurodegenerative diseases, such as dementia, with Eisai’s extensive experience in drug discovery and development.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            December 14, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery

                            Recipient : Eisai

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Washington University School of Medicine

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Washington University School of Medicine

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : BostonGene

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BostonGene Announces Publication in Cell Reports Revealing Spatial Heterogeneity in the Tumor Microenvironment...

                            Details : Study finds that tumor behavior specificities linked with patient responses, and the MxIF analyses identified 14 unique cellular neighborhoods in multi-region tumors that can be utilized to optimize treatment strategies for patients with ccRCC.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Not Applicable

                            October 04, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : BostonGene

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Washington University School of Medicine

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Washington University School of Medicine

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BBV154

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Recipient : Ocugen

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Ocugen Announces Agreement With Washington University in St. Louis for Commercialization of Intranasal COVID-1...

                            Details : Ocugen’s intranasal vaccine candidate BBV154, is a recombinant, replication-deficient, adenovirus-vectored vaccine with a prefusion stabilized spike protein. In addition, intranasal delivery provides an alternative to those who are hesitant to receive ...

                            Brand Name : BBV154

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            September 28, 2022

                            Lead Product(s) : BBV154

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Recipient : Ocugen

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Washington University School of Medicine

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Washington University School of Medicine

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bomedemstat,Atezolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Imago BioSciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Study of Bomedemstat in Combinat...

                            Details : A combination of IMG-7289 (bomedemstat), in solid tumors enhances their immunogenicity, and atezolizumab, a checkpoint inhibitor, represents in lung cancer treatment, may provide long-term disease management possibilities for patients with small cell lun...

                            Brand Name : IMG-7289

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 09, 2022

                            Lead Product(s) : Bomedemstat,Atezolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Imago BioSciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Washington University School of Medicine

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Washington University School of Medicine

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tixagevimab,Cilgavimab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Recipient : AstraZeneca

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            EVUSHELD™ Long-acting Antibody Combination Retains Neutralizing Activity Against Omicron Variants Including ...

                            Details : New preclinical authentic ‘live’ virus data demonstrated that EVUSHELD retains potent neutralizing activity against emerging and highly transmissible Omicron SARS-CoV-2 BA.2 subvariant. The data also showed that EVUSHELD retains activity against Omic...

                            Brand Name : Evusheld

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 21, 2022

                            Lead Product(s) : Tixagevimab,Cilgavimab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Recipient : AstraZeneca

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Washington University School of Medicine

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Washington University School of Medicine

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HT-ALZ

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Hoth Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Hoth Therapeutics Announces Sponsored Research Agreement with Washington University for Novel Alzheimer's Ther...

                            Details : This Sponsored Research Agreement with Washington University in St. Louis aims to support the continued research and development of HT-ALZ, a novel therapeutic for the treatment of symptoms related to Alzheimer's disease.

                            Brand Name : HT-ALZ

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 07, 2021

                            Lead Product(s) : HT-ALZ

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Hoth Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Washington University School of Medicine

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Washington University School of Medicine

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PRGN-3005

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Precigen

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Precigen Doses First Patients with UltraCAR-T® Cells in Ongoing PRGN-3005 and PRGN-3006 Phase 1 Clinical Tria...

                            Details : UltraPorator system is an exclusive device and proprietary software solution for the scale-up of rapid and cost-effective, decentralized manufacturing of UltraCAR-T therapies.

                            Brand Name : PRGN-3005 UltraCAR-T

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            November 16, 2020

                            Lead Product(s) : PRGN-3005

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Precigen

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Washington University School of Medicine

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Washington University School of Medicine

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Covid 19 vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Bharat Biotech

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Bharat Biotech Inks Licensing Deal with Washington University School of Medicine to advance COVID-19 Intranasa...

                            Details : This vaccine expands Bharat’s portfolio of vaccines that are currently being developed and are in various stages of clinical development including COVAXIN® which is currently in Phase II human clinical trials in India.

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            September 23, 2020

                            Lead Product(s) : Covid 19 vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Bharat Biotech

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth